Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma

Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective tre...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-12, Vol.11, p.603591
Main Authors: Zhang, Jie Qing, Zhao, Bing Bing, Wang, Mao Mao, Li, Li
Format: Article
Language:English
Subjects:
case report
gynecologic oncology
maintenance therapy
niraparib
Oncology
ovarian carcinosarcoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.603591